^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MOv18 IgE

    i
    Other names: MOv18 IgE, MOv18
    Associations

    News

    Trials
    Company:
    Cancer Research UK, Epsilogen
    Drug class:
    Folate receptor 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability. (PubMed, MAbs)
    MOv18 IgE retains monomeric purity in response to formulation and stress conditions, confirming stability. Our results offer crucial guidance for future IgE-based drug development.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    MOv18 IgE
    8ms
    Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction. (PubMed, Nat Commun)
    We demonstrate that IgE induces hyperinflammatory repolarised states of patient-derived macrophages to inhibit Treg cell immunosuppression. These processes may collectively promote immune activation in ovarian cancer patients receiving IgE therapy.
    Journal
    |
    CD8 (cluster of differentiation 8) • FOLR1 ( Folate receptor alpha ) • CD68 (CD68 Molecule)
    |
    MOv18 IgE
    9ms
    Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha. (PubMed, Allergy)
    Urticarial skin reactions following MOv18 IgE treatment were unlikely to result from allergic mechanisms or skin antigen recognition. The clinical presentation is consistent with infusion-related reactions commonly observed with monoclonal antibody treatments.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    MOv18 IgE
    1year
    A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Epsilogen Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MOv18 IgE
    over1year
    A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Epsilogen Ltd
    New P1 trial • Metastases
    |
    MOv18 IgE
    over2years
    Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. (PubMed, Nat Commun)
    The safety profile is tolerable and maximum tolerated dose has not been reached, with evidence of anti-tumour activity observed in a patient with ovarian cancer. These results demonstrate the potential of IgE therapy for cancer.
    P1 data • Journal • Metastases
    |
    FOLR1 ( Folate receptor alpha )
    |
    MOv18 IgE